Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, cash reserves at Lyra Therapeutics Inc fell by 10.20m. Cash Flow from Financing totalled 65.69m or 4,216.37% of revenues. In addition the company used 63.30m for operations while cash used for investing totalled 12.58m.
Cash flow per share | -1.63 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.4733 |
---|---|
Tangible book value per share | 0.4733 |
More ▼
Balance sheet in USDView more
Current ratio | 3.60 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼